BOL-148

BOL-148 is a **small molecule** ergoline and non-hallucinogenic analog of lysergic acid diethylamide that has been investigated primarily for **cluster headache**. It interacts with **serotonin receptors**, especially the **serotonin 2A receptor**, but appears to have markedly reduced hallucinogenic signaling relative to LSD, including weak recruitment of beta-arrestin2 and a lower tendency to produce tolerance in preclinical studies. The compound has also shown **psychoplastogenic** and antidepressant-like effects in animal models. Development and supply activities mentioned for BOL-148 include work by **Ceruvia Lifesciences**, with additional formulation or platform-related activity reported from **Core One Labs** and **Akome Biotech**.

Other names

2-bromo-lysergic acid diethylamide2-bromo-LSD